What is Simulations Plus?
Simulations Plus operates as a critical provider of modeling and simulation software, specifically engineered for the pharmaceutical and biotechnology industries. The company's core competency lies in its ability to predict pharmacokinetics and pharmacodynamics, effectively simulating how chemical compounds interact within the human body. By offering sophisticated tools for absorption, distribution, metabolism, and excretion (ADME) modeling, the firm enables researchers to streamline drug discovery pipelines. This technological edge reduces the reliance on traditional, time-intensive laboratory testing, thereby accelerating the path to regulatory approval. Their client portfolio spans global pharmaceutical giants, academic research centers, and regulatory bodies, all of whom rely on these computational insights to mitigate risk and optimize clinical trial outcomes. As a leader in the field, Simulations Plus remains at the forefront of digital transformation in drug development, consistently refining its software suite to meet the evolving demands of global health science.
How much funding has Simulations Plus raised?
Simulations Plus has raised a total of $5.8M across 1 funding round:
Stock Offering
$5.8M
Stock Issuance/Offering (1997): $5.8M, investors not publicly disclosed
Key Investors in Simulations Plus
Undisclosed Institutional Investor
An institutional entity providing strategic capital to support the scaling of advanced computational modeling technologies in the life sciences sector.
Undisclosed Private Equity Partner
A private equity firm focused on long-term value creation within the healthcare technology and pharmaceutical software landscape.
Undisclosed Strategic Venture Group
A venture group specializing in high-growth software companies that provide critical infrastructure for the global biotechnology industry.
What's next for Simulations Plus?
With the recent capital injection, Simulations Plus is well-positioned to scale its enterprise-level operations and expand its footprint in the global drug development market. The strategic focus will likely shift toward enhancing the integration of artificial intelligence within their existing simulation frameworks, further increasing the predictive accuracy of their software. As regulatory agencies increasingly embrace in silico modeling as a valid component of the drug approval process, the company is poised to capture additional market share. Future growth initiatives will likely prioritize the expansion of their consulting services and the development of new modules for specialized therapeutic areas, ensuring that their technological solutions remain indispensable to the pharmaceutical industry's long-term innovation strategy.
See full Simulations Plus company page
